Jun Lei
Wuhan University
12 Papers
1 Citations
Jun Lei is an academic researcher from Wuhan University. The author has contributed to research in topics: Biology & Medicine. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
A Cas12a ortholog with stringent PAM recognition followed by low off-target editing rates for genome editing
Peng Chen,Jin Zhou,Yibin Wan,Huan Liu,Yongzheng Li,Zhaoxin Liu,Hongjian Wang,Jun Lei,Kai Zhao,Yiliang Zhang,Yan Wang,Xinghua Zhang,Lei Yin +12 more
TL;DR: This study shows that CeCas12a nuclease is active in human cells and the stringency of PAM recognition could be an important factor shaping off-target editing in gene editing.
Combined effects of avasimibe immunotherapy, doxorubicin chemotherapy, and metal-organic frameworks nanoparticles on breast cancer
TL;DR: The combinational usage of avasimibe and a safe pH sensitive nano‐drug delivery system composing of DOX and metal–organic frameworks nanoparticles (MNPs) demonstrated that DOX–MNPs treatment inhibited tumor growth with good safety profile and avasIMibe treatment combined DOX-MNPstreatment exhibited a better efficacy than monotherapies in 4T1 breast cancer therapy.
49
Cas12a variants designed for lowergenome-wide off-target effectthrough stringent PAM recognition.
Jin Zhou,Peng Chen,Hongjian Wang,Huan Liu,Yongzheng Li,Youpeng Zhang,Yankang Wu,Chonil Paek,Zaiqiao Sun,Jun Lei,Lei Yin +10 more
TL;DR: Wang et al. as mentioned in this paper designed a variant of LbCas12a (termed Lb-K538R) with more stringent PAM recognition, lower off-targeting capability, and similar editing efficiency.
20
Engineering of Cas12a nuclease variants with enhanced genome-editing specificity.
Jin Zhou,Huan Liu,Erchi Zhou,Boxiao He,Yankang Wu,Hongjian Wang,Zaiqiao Sun,Chon-Il Paek,Jun Lei,Yongshun Chen,Xinghua Zhang,Lei Yin +11 more
TL;DR: Engineering of Cas12a nuclease variants with enhanced genome-editing specificity results in a variant with low off-target effects and improved performance in human cells.
4
Structural Basis for Unusual TCR CDR3β Usage Against an Immunodominant HIV-1 Gag Protein Peptide Restricted to an HLA-B*81:01 Molecule
TL;DR: A portrait of how CD8+ T cells engage in HIV-mediated T cell response is provided, revealing that this TCR can recognize TL9 epitope and several mutant versions, which might explain the correlation of T18A TCR with better clinic outcomes despite the relative high mutation rate of HIV.